1 Report Overview 1.1 Research Scope 1.2 Market Segment by Type 1.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate by Type (2017 VS 2021 VS 2028) 1.2.2 Prescription Drugs 1.2.3 OTC Drugs 1.3 Market Segment by Application 1.3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Application (2017 VS 2021 VS 2028) 1.3.2 Childhood (0-6) 1.3.3 Juvenile (7-17) 1.3.4 Youth (18-40) 1.3.5 Middle Aged (41-60) 1.3.6 Elderly (Above 60) 1.4 Study Objectives 1.5 Years Considered 2 Market Perspective 2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size (2017-2028) 2.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) 2.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (2017-2028) 2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028 2.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Regions (2017-2022) 2.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Regions (2017-2022) 2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Forecast by Region 2.3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Region (2023-2028) 2.3.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast by Region (2023-2028) 2.4 Global Top Anti-Obesity Drugs (Anti-obesity Medication) Regions (Countries) Ranking by Market Size 2.5 Anti-Obesity Drugs (Anti-obesity Medication) Market Dynamics 2.5.1 Anti-Obesity Drugs (Anti-obesity Medication) Market Trends 2.5.2 Anti-Obesity Drugs (Anti-obesity Medication) Market Drivers 2.5.3 Anti-Obesity Drugs (Anti-obesity Medication) Market Challenges 2.5.4 Anti-Obesity Drugs (Anti-obesity Medication) Market Restraints 3 Competitive Landscape by Manufacturers 3.1 Global Top Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers by Sales (2017-2022) 3.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Manufacturers (2017-2022) 3.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Manufacturers (2017-2022) 3.1.3 Global 5 and 10 Largest Manufacturers by Anti-Obesity Drugs (Anti-obesity Medication) Sales in 2021 3.2 Global Top Manufacturers Anti-Obesity Drugs (Anti-obesity Medication) by Revenue 3.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Manufacturers (2017-2022) 3.2.2 Top Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers Covered: Ranking by Revenue 3.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Manufacturers (2017-2022) 3.2.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Concentration Ratio (CR5 and HHI) 3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anti-Obesity Drugs (Anti-obesity Medication) as of 2021) 3.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Average Selling Price (ASP) by Manufacturers 3.5 Key Manufacturers Anti-Obesity Drugs (Anti-obesity Medication) Plants/Factories Distribution and Area Served 3.6 Date of Key Manufacturers Enter into Anti-Obesity Drugs (Anti-obesity Medication) Market 3.7 Key Manufacturers Anti-Obesity Drugs (Anti-obesity Medication) Product Offered 3.8 Mergers & Acquisitions, Expansion Plans 4 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type 4.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Historic Market Review by Type (2017-2022) 4.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2017-2022) 4.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2017-2022) 4.1.3 Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2017-2022) 4.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Estimates and Forecasts by Type (2023-2028) 4.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Type (2023-2028) 4.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast by Type (2023-2028) 4.2.3 Anti-Obesity Drugs (Anti-obesity Medication) Price Forecast by Type (2023-2028) 5 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application 5.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Historic Market Review by Application (2017-2022) 5.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2017-2022) 5.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2017-2022) 5.1.3 Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2017-2022) 5.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Estimates and Forecasts by Application (2023-2028) 5.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Application (2023-2028) 5.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast by Application (2023-2028) 5.2.3 Anti-Obesity Drugs (Anti-obesity Medication) Price Forecast by Application (2023-2028) 6 North America 6.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Company 6.1.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Company (2017-2022) 6.1.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Company (2017-2022) 6.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type 6.2.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2017-2028) 6.2.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2017-2028) 6.3 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application 6.3.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2017-2028) 6.3.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2017-2028) 6.4 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country 6.4.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2017-2028) 6.4.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2017-2028) 6.4.3 U.S. 6.4.4 Canada 7 Europe 7.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Company 7.1.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Company (2017-2022) 7.1.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Company (2017-2022) 7.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type 7.2.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2017-2028) 7.2.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2017-2028) 7.3 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application 7.3.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2017-2028) 7.3.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2017-2028) 7.4 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country 7.4.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2017-2028) 7.4.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2017-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 8 Asia Pacific 8.1 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Company 8.1.1 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Company (2017-2022) 8.1.2 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Company (2017-2022) 8.2 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type 8.2.1 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2017-2028) 8.2.2 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2017-2028) 8.3 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application 8.3.1 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2017-2028) 8.3.2 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2017-2028) 8.4 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Region 8.4.1 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region 8.4.2 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 India 8.4.7 Australia 8.4.8 China Taiwan 8.4.9 Indonesia 8.4.10 Thailand 8.4.11 Malaysia 9 Latin America 9.1 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Company 9.1.1 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Company (2017-2022) 9.1.2 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Company (2017-2022) 9.2 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type 9.2.1 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2017-2028) 9.2.2 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2017-2028) 9.3 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application 9.3.1 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2017-2028) 9.3.2 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2017-2028) 9.4 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country 9.4.1 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2017-2028) 9.4.2 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2017-2028) 9.4.3 Mexico 9.4.4 Brazil 9.4.5 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Breakdown by Company 10.1.1 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Company (2017-2022) 10.1.2 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Company (2017-2022) 10.2 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Type 10.2.1 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2017-2028) 10.2.2 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2017-2028) 10.3 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Application 10.3.1 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2017-2028) 10.3.2 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2017-2028) 10.4 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country 10.4.1 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2017-2028) 10.4.2 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2017-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Company Profiles 11.1 Zafgan 11.1.1 Zafgan Corporation Information 11.1.2 Zafgan Overview 11.1.3 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.1.4 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.1.5 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis 11.1.6 Zafgan Recent Developments 11.2 Vivus 11.2.1 Vivus Corporation Information 11.2.2 Vivus Overview 11.2.3 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.2.4 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.2.5 Vivus Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis 11.2.6 Vivus Recent Developments 11.3 Shionogi 11.3.1 Shionogi Corporation Information 11.3.2 Shionogi Overview 11.3.3 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.3.4 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.3.5 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis 11.3.6 Shionogi Recent Developments 11.4 Sanofi 11.4.1 Sanofi Corporation Information 11.4.2 Sanofi Overview 11.4.3 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.4.4 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.4.5 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis 11.4.6 Sanofi Recent Developments 11.5 Rhythm Pharmaceuticals 11.5.1 Rhythm Pharmaceuticals Corporation Information 11.5.2 Rhythm Pharmaceuticals Overview 11.5.3 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.5.4 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.5.5 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis 11.5.6 Rhythm Pharmaceuticals Recent Developments 11.6 Pfizer 11.6.1 Pfizer Corporation Information 11.6.2 Pfizer Overview 11.6.3 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.6.4 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.6.5 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis 11.6.6 Pfizer Recent Developments 11.7 Orexigen Therapeutics 11.7.1 Orexigen Therapeutics Corporation Information 11.7.2 Orexigen Therapeutics Overview 11.7.3 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.7.4 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.7.5 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis 11.7.6 Orexigen Therapeutics Recent Developments 11.8 Novo Nordisk 11.8.1 Novo Nordisk Corporation Information 11.8.2 Novo Nordisk Overview 11.8.3 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.8.4 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.8.5 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis 11.8.6 Novo Nordisk Recent Developments 11.9 Norgine 11.9.1 Norgine Corporation Information 11.9.2 Norgine Overview 11.9.3 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.9.4 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.9.5 Norgine Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis 11.9.6 Norgine Recent Developments 11.10 Nalpropion Pharmaceuticals Inc. 11.10.1 Nalpropion Pharmaceuticals Inc. Corporation Information 11.10.2 Nalpropion Pharmaceuticals Inc. Overview 11.10.3 Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.10.4 Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.10.5 Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis 11.10.6 Nalpropion Pharmaceuticals Inc. Recent Developments 11.11 Merck 11.11.1 Merck Corporation Information 11.11.2 Merck Overview 11.11.3 Merck Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.11.4 Merck Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.11.5 Merck Recent Developments 11.12 GlaxoSmithKline 11.12.1 GlaxoSmithKline Corporation Information 11.12.2 GlaxoSmithKline Overview 11.12.3 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.12.4 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.12.5 GlaxoSmithKline Recent Developments 11.13 F.Hoffmann-La Roche 11.13.1 F.Hoffmann-La Roche Corporation Information 11.13.2 F.Hoffmann-La Roche Overview 11.13.3 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.13.4 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.13.5 F.Hoffmann-La Roche Recent Developments 11.14 Eisai 11.14.1 Eisai Corporation Information 11.14.2 Eisai Overview 11.14.3 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.14.4 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.14.5 Eisai Recent Developments 11.15 Boehringer Ingelheim 11.15.1 Boehringer Ingelheim Corporation Information 11.15.2 Boehringer Ingelheim Overview 11.15.3 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.15.4 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.15.5 Boehringer Ingelheim Recent Developments 11.16 Bayer AG 11.16.1 Bayer AG Corporation Information 11.16.2 Bayer AG Overview 11.16.3 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.16.4 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.16.5 Bayer AG Recent Developments 11.17 AstraZeneca 11.17.1 AstraZeneca Corporation Information 11.17.2 AstraZeneca Overview 11.17.3 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.17.4 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.17.5 AstraZeneca Recent Developments 11.18 Arena Pharmaceuticals 11.18.1 Arena Pharmaceuticals Corporation Information 11.18.2 Arena Pharmaceuticals Overview 11.18.3 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.18.4 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.18.5 Arena Pharmaceuticals Recent Developments 11.19 Amylin 11.19.1 Amylin Corporation Information 11.19.2 Amylin Overview 11.19.3 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.19.4 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.19.5 Amylin Recent Developments 11.20 Alizyme 11.20.1 Alizyme Corporation Information 11.20.2 Alizyme Overview 11.20.3 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022) 11.20.4 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Products and Services 11.20.5 Alizyme Recent Developments 12 Value Chain and Sales Channels Analysis 12.1 Anti-Obesity Drugs (Anti-obesity Medication) Value Chain Analysis 12.2 Anti-Obesity Drugs (Anti-obesity Medication) Key Raw Materials 12.2.1 Key Raw Materials 12.2.2 Raw Materials Key Suppliers 12.3 Anti-Obesity Drugs (Anti-obesity Medication) Production Mode & Process 12.4 Anti-Obesity Drugs (Anti-obesity Medication) Sales and Marketing 12.4.1 Anti-Obesity Drugs (Anti-obesity Medication) Sales Channels 12.4.2 Anti-Obesity Drugs (Anti-obesity Medication) Distributors 12.5 Anti-Obesity Drugs (Anti-obesity Medication) Customers 13 Research Findings and Conclusion 14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.2 Data Source 14.2 Author Details 14.3 Disclaimer

List of Tables Table 1. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million) Table 2. Major Manufacturers of Prescription Drugs Table 3. Major Manufacturers of OTC Drugs Table 4. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million) Table 5. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028 Table 6. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2017-2022) & (K Units) Table 7. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2017-2022) Table 8. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2017-2022) & (US$ Million) Table 9. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2017-2022) Table 10. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecast by Region (2023-2028) & (K Units) Table 11. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share Forecast by Region (2023-2028) Table 12. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Forecast by Region (2023-2028) & (US$ Million) Table 13. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share Forecast by Region (2023-2028) Table 14. Top Anti-Obesity Drugs (Anti-obesity Medication) Regions (Countries) Ranking by Market Size (US$ Million) in 2021 Table 15. Anti-Obesity Drugs (Anti-obesity Medication) Market Trends Table 16. Anti-Obesity Drugs (Anti-obesity Medication) Market Drivers Table 17. Anti-Obesity Drugs (Anti-obesity Medication) Market Challenges Table 18. Anti-Obesity Drugs (Anti-obesity Medication) Market Restraints Table 19. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Manufacturers (2017-2022) & (K Units) Table 20. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Manufacturers (2017-2022) Table 21. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Manufacturers (2017-2022) & (US$ Million) Table 22. Ranking of Global Top Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers by Revenue (US$ Million) in 2021 Table 23. Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Manufacturers (2017-2022) Table 24. Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers Market Concentration Ratio (CR5 and HHI) Table 25. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anti-Obesity Drugs (Anti-obesity Medication) as of 2021) Table 26. Key Manufacturers Anti-Obesity Drugs (Anti-obesity Medication) Average Selling Price (ASP) & (2017-2022) & (USD/Unit) Table 27. Key Manufacturers Anti-Obesity Drugs (Anti-obesity Medication) Plants/Factories Distribution Table 28. Key Manufacturers Anti-Obesity Drugs (Anti-obesity Medication) Area Served Table 29. Date of Key Manufacturers Enter into Anti-Obesity Drugs (Anti-obesity Medication) Market Table 30. Key Manufacturers Anti-Obesity Drugs (Anti-obesity Medication) Product Type Table 31. Mergers & Acquisitions, Expansion Plans Table 32. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units) by Type (2017-2022) Table 33. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Type (2017-2022) Table 34. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (US$ Million) Market Share by Type (2017-2022) Table 35. Global Anti-Obesity Drugs (Anti-obesity Medication) Price (K Units) by Type (2017-2022) Table 36. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units) by Type (2023-2028) Table 37. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Type (2023-2028) Table 38. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (US$ Million) Market Share by Type (2023-2028) Table 39. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Type (2023-2028) Table 40. Global Anti-Obesity Drugs (Anti-obesity Medication) Price (K Units) by Type (2023-2028) Table 41. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units) by Application (2017-2022) Table 42. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Application (2017-2022) Table 43. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (US$ Million) Market Share by Application (2017-2022) Table 44. Global Anti-Obesity Drugs (Anti-obesity Medication) Price (K Units) by Application (2017-2022) Table 45. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units) by Application (2023-2028) Table 46. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Application (2023-2028) Table 47. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (US$ Million) Market Share by Application (2023-2028) Table 48. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Application (2023-2028) Table 49. Global Anti-Obesity Drugs (Anti-obesity Medication) Price (K Units) by Application (2023-2028) Table 50. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Company (2017-2022) & (K Units) Table 51. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Company (2017-2022) Table 52. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Company (2017-2022) & (US$ Million) Table 53. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Company (2017-2022) Table 54. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2017-2022) & (K Units) Table 55. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2023-2028) & (K Units) Table 56. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2017-2022) & (US$ Million) Table 57. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2023-2028) & (US$ Million) Table 58. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2017-2022) & (K Units) Table 59. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2023-2028) & (K Units) Table 60. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2017-2022) & (US$ Million) Table 61. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2023-2028) & (US$ Million) Table 62. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2017-2022) & (K Units) Table 63. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2023-2028) & (K Units) Table 64. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2017-2022) & (US$ Million) Table 65. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2023-2028) & (US$ Million) Table 66. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Company (2017-2022) & (K Units) Table 67. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Company (2017-2022) Table 68. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Company (2017-2022) & (US$ Million) Table 69. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Company (2017-2022) Table 70. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2017-2022) & (K Units) Table 71. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2023-2028) & (K Units) Table 72. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2017-2022) & (US$ Million) Table 73. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2023-2028) & (US$ Million) Table 74. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2017-2022) & (K Units) Table 75. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2023-2028) & (K Units) Table 76. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2017-2022) & (US$ Million) Table 77. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2023-2028) & (US$ Million) Table 78. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2017-2022) & (K Units) Table 79. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2023-2028) & (K Units) Table 80. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2017-2022) & (US$ Million) Table 81. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2023-2028) & (US$ Million) Table 82. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Company (2017-2022) & (K Units) Table 83. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Company (2017-2022) Table 84. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Company (2017-2022) & (US$ Million) Table 85. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Company (2017-2022) Table 86. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2017-2022) & (K Units) Table 87. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2023-2028) & (K Units) Table 88. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2017-2022) & (US$ Million) Table 89. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2023-2028) & (US$ Million) Table 90. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2017-2022) & (K Units) Table 91. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2023-2028) & (K Units) Table 92. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2017-2022) & (US$ Million) Table 93. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2023-2028) & (US$ Million) Table 94. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2017-2022) & (K Units) Table 95. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2023-2028) & (K Units) Table 96. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2017-2022) & (US$ Million) Table 97. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2023-2028) & (US$ Million) Table 98. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Company (2017-2022) & (K Units) Table 99. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Company (2017-2022) Table 100. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Company (2017-2022) & (US$ Million) Table 101. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Company (2017-2022) Table 102. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2017-2022) & (K Units) Table 103. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2023-2028) & (K Units) Table 104. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2017-2022) & (US$ Million) Table 105. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2023-2028) & (US$ Million) Table 106. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2017-2022) & (K Units) Table 107. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2023-2028) & (K Units) Table 108. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2017-2022) & (US$ Million) Table 109. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2023-2028) & (US$ Million) Table 110. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2017-2022) & (K Units) Table 111. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2023-2028) & (K Units) Table 112. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2017-2022) & (US$ Million) Table 113. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2023-2028) & (US$ Million) Table 114. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Company (2017-2022) & (K Units) Table 115. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Company (2017-2022) Table 116. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Company (2017-2022) & (US$ Million) Table 117. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Company (2017-2022) Table 118. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2017-2022) & (K Units) Table 119. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2023-2028) & (K Units) Table 120. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2017-2022) & (US$ Million) Table 121. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2023-2028) & (US$ Million) Table 122. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2017-2022) & (K Units) Table 123. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2023-2028) & (K Units) Table 124. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2017-2022) & (US$ Million) Table 125. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2023-2028) & (US$ Million) Table 126. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2017-2022) & (K Units) Table 127. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2023-2028) & (K Units) Table 128. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2017-2022) & (US$ Million) Table 129. Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2023-2028) & (US$ Million) Table 130. Zafgan Corporation Information Table 131. Zafgan Description and Overview Table 132. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 133. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 134. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis Table 135. Zafgan Recent Developments Table 136. Vivus Corporation Information Table 137. Vivus Description and Overview Table 138. Vivus Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 139. Vivus Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 140. Vivus Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis Table 141. Vivus Recent Developments Table 142. Shionogi Corporation Information Table 143. Shionogi Description and Overview Table 144. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 145. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 146. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis Table 147. Shionogi Recent Developments Table 148. Sanofi Corporation Information Table 149. Sanofi Description and Overview Table 150. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 151. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 152. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis Table 153. Sanofi Recent Developments Table 154. Rhythm Pharmaceuticals Corporation Information Table 155. Rhythm Pharmaceuticals Description and Overview Table 156. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 157. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 158. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis Table 159. Rhythm Pharmaceuticals Recent Developments Table 160. Pfizer Corporation Information Table 161. Pfizer Description and Overview Table 162. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 163. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 164. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis Table 165. Pfizer Recent Developments Table 166. Orexigen Therapeutics Corporation Information Table 167. Orexigen Therapeutics Description and Overview Table 168. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 169. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 170. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis Table 171. Orexigen Therapeutics Recent Developments Table 172. Novo Nordisk Corporation Information Table 173. Novo Nordisk Description and Overview Table 174. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 175. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 176. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis Table 177. Novo Nordisk Recent Developments Table 178. Norgine Corporation Information Table 179. Norgine Description and Overview Table 180. Norgine Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 181. Norgine Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 182. Norgine Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis Table 183. Norgine Recent Developments Table 184. Nalpropion Pharmaceuticals Inc. Corporation Information Table 185. Nalpropion Pharmaceuticals Inc. Description and Overview Table 186. Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 187. Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 188. Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) SWOT Analysis Table 189. Nalpropion Pharmaceuticals Inc. Recent Developments Table 190. Merck Corporation Information Table 191. Merck Description and Overview Table 192. Merck Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 193. Merck Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 194. Merck Recent Developments Table 195. GlaxoSmithKline Corporation Information Table 196. GlaxoSmithKline Description and Overview Table 197. GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 198. GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 199. GlaxoSmithKline Recent Developments Table 200. F.Hoffmann-La Roche Corporation Information Table 201. F.Hoffmann-La Roche Description and Overview Table 202. F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 203. F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 204. F.Hoffmann-La Roche Recent Developments Table 205. Eisai Corporation Information Table 206. Eisai Description and Overview Table 207. Eisai Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 208. Eisai Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 209. Eisai Recent Developments Table 210. Boehringer Ingelheim Corporation Information Table 211. Boehringer Ingelheim Description and Overview Table 212. Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 213. Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 214. Boehringer Ingelheim Recent Developments Table 215. Bayer AG Corporation Information Table 216. Bayer AG Description and Overview Table 217. Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 218. Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 219. Bayer AG Recent Developments Table 220. AstraZeneca Corporation Information Table 221. AstraZeneca Description and Overview Table 222. AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 223. AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 224. AstraZeneca Recent Developments Table 225. Arena Pharmaceuticals Corporation Information Table 226. Arena Pharmaceuticals Description and Overview Table 227. Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 228. Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 229. Arena Pharmaceuticals Recent Developments Table 230. Amylin Corporation Information Table 231. Amylin Description and Overview Table 232. Amylin Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 233. Amylin Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 234. Amylin Recent Developments Table 235. Alizyme Corporation Information Table 236. Alizyme Description and Overview Table 237. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2017-2022) Table 238. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product and Services Table 239. Alizyme Recent Developments Table 240. Key Raw Materials Lists Table 241. Raw Materials Key Suppliers Lists Table 242. Anti-Obesity Drugs (Anti-obesity Medication) Distributors List Table 243. Anti-Obesity Drugs (Anti-obesity Medication) Customers List Table 244. Research Programs/Design for This Report Table 245. Key Data Information from Secondary Sources Table 246. Key Data Information from Primary Sources List of Figures Figure 1. Anti-Obesity Drugs (Anti-obesity Medication) Product Picture Figure 2. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type in 2021 & 2028 Figure 3. Prescription Drugs Product Picture Figure 4. OTC Drugs Product Picture Figure 5. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application in 2021 & 2028 Figure 6. Childhood (0-6) Use Case Figure 7. Juvenile (7-17) Use Case Figure 8. Youth (18-40) Use Case Figure 9. Middle Aged (41-60) Use Case Figure 10. Elderly (Above 60) Use Case Figure 11. Anti-Obesity Drugs (Anti-obesity Medication) Report Years Considered Figure 12. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 13. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size 2017-2028 (US$ Million) Figure 14. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (2017-2022) & (K Units) Figure 15. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Market Share by Region: 2021 VS 2028 Figure 16. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2017-2022) Figure 17. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region in 2021 Figure 18. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region in 2017 VS 2021 Figure 19. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Manufacturers in 2021 Figure 20. The 5 and 10 Largest Manufacturers in the World: Market Share by Anti-Obesity Drugs (Anti-obesity Medication) Sales in 2021 Figure 21. Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Manufacturers in 2021 Figure 22. Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021 Figure 23. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Type (2017-2022) Figure 24. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate by Type in 2017 & 2021 Figure 25. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Application (2017-2022) Figure 26. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate by Application in 2017 & 2021 Figure 27. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2017-2028) Figure 28. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2017-2028) Figure 29. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2017-2028) Figure 30. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2017-2028) Figure 31. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Country (2017-2028) Figure 32. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Country (2017-2028) Figure 33. U.S. Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 34. Canada Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 35. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2017-2028) Figure 36. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2017-2028) Figure 37. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2017-2028) Figure 38. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2017-2028) Figure 39. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Country (2017-2028) Figure 40. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Country (2017-2028) Figure 41. Germany Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 42. France Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 43. U.K. Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 44. Italy Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 45. Russia Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 46. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2017-2028) Figure 47. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2017-2028) Figure 48. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2017-2028) Figure 49. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2017-2028) Figure 50. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Region (2017-2028) Figure 51. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Region (2017-2028) Figure 52. China Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 53. Japan Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 54. South Korea Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 55. India Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 56. Australia Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 57. China Taiwan Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 58. Indonesia Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 59. Thailand Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 60. Malaysia Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2017-2028) & (US$ Million) Figure 61. Latin America Anti-Obesity Drugs (Anti-obesity Medication

Zafgan Vivus Shionogi Sanofi Rhythm Pharmaceuticals Pfizer Orexigen Therapeutics Novo Nordisk Norgine Nalpropion Pharmaceuticals Inc. Merck GlaxoSmithKline F.Hoffmann-La Roche Eisai Boehringer Ingelheim Bayer AG AstraZeneca Arena Pharmaceuticals Amylin Alizyme